Table 1.

Patients’ characteristics. Values are expressed in n (%) for qualitative variables and in median (range) for quantitative variables. P-values < 0.05 are indicated in bold.

	Training cohort		Validation cohort	P-value†
	ACA	ACC	ACC
n	42	49 + 4*	36
Age (years)	51 (25–85)	47 (21–73)	49 (20–81)	0.34
Sex				0.33
Female	33 (79%)	41 (77%)	24 (67%)
Male	9 (21%)	12 (23%)	12 (33%)
Cortisol secretion				0.46
Yes	32 (78%)	33 (62%)	13 (52%)
No	9 (22%)	20 (38%)	12 (48%)
Not available	1		11
ENSAT stage				0.82
I	33 (82%)	8 (15%)	3 (8%)
II	7 (18%)	26 (49%)	18 (50%)
III		12 (23%)	10 (28%)
IV		7 (13%)	5 (14%)
Not available	2
Subtype				0.005
Classical	33 (79%)	43 (81%)	36 (100%)
Oncocytic	9 (21%)	10 (19%)	0 (0%)
Resection
R0	42 (100%)	46 (87%)	24 (67%)	0.08
R1		2 (4%)	3 (8%)
R2		0 (0%)	2 (6%)
RX		5 (9%)	7 (19%)
Weiss score				0.17
0–1	26 (62%)
2	13 (31%)
3	3 (7%)	8 (15%)	1 (3%)
4–6		17 (32%)	14 (47%)
7–9		28 (53%)	15 (50%)
Ki-67				0.008
<10%	29 (100%)	23 (49%)	6 (17%)
10–19%	0 (0%)	7 (15%)	10 (28%)
≥20%	0 (0%)	17 (36%)	20 (56%)
Not available	13	6
Relapse or metastases				<10−4
No	34 (100%)	33 (62%)	6 (17%)
Yes	0 (0%)	20 (38%)	30 (83%)
Not available	8
Death				0.27
No	34 (100%)	36 (68%)	20 (56%)
Yes	0 (0%)	17 (32%)	16 (44%)
Not available	8

*ACC (n = 49) and ACT of uncertain malignant potential (n = 4); ^†P-values are provided for the comparison between ACC and ACT of uncertain malignant potential from the training cohort and ACC from the validation cohort.